Description: SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.
Home Page: www.sonnetbio.com
SONN Technical Analysis
100 Overlook Center
Princeton,
NJ
08540
United States
Phone:
609-375-2227
Officers
Name | Title |
---|---|
Dr. Pankaj Mohan Ph.D. | Founder, Chairman. CEO & Pres |
Dr. John K. Cini Ph.D. | Chief Scientific Officer & Co-Founder |
Mr. Jay Cross | Chief Financial Officer |
Ms. Susan Dexter | Chief Technical Officer |
Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
Mr. Manuel Dafonseca | Head of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 9.454 |
Price-to-Sales TTM: | 9.0917 |
IPO Date: | 2006-10-31 |
Fiscal Year End: | December |
Full Time Employees: | 12 |